Investigation into irregularities in the pharmaceutical sector
The Anti-Corruption and Good Government Secretariat, under the leadership of Raquel Buenrostro, has initiated investigation processes against 16 pharmaceutical companies for alleged irregularities in the marketing of medicines. These companies are part of a broader group of 59 entities under scrutiny for various questionable practices, including falsification of regulatory documentation.
During the morning conference with President Claudia Sheinbaum, Buenrostro explained that one of the companies, Biomedics, has already been disqualified and could face criminal charges for altering records of the COFEPRIS (Federal Commission for the Protection against Health Risks). “We are advancing in all investigations. Last week we disqualified one firm, and now we are preparing legal action against another for falsifying documents,” said the official.
Key findings and inter-institutional collaboration
The analysis of the files revealed the manipulation of more than 650 health record keys, which has motivated close coordination with the Secretariat of Health and COFEPRIS to optimize the purchasing processes and avoid future abuses. “We have identified systemic failures that facilitated these irregularities. We are working on more transparent protocols,” Buenrostro explained.
Among the 59 companies investigated, some have no relationship with the health sector. “There are real estate companies and fuel distributors involved in pharmaceutical tenders, which shows possible diversions of resources,” said the owner. To delve deeper into these cases, the agency will collaborate with the Tax Administration Service (SAT) and customs authorities.
Impact on medicine shortages: The irregularities detected have exacerbated the shortage of drugs in Mexico, a critical problem that affects chronic patients. The falsification of permits and the participation of companies without experience in the pharmaceutical field have distorted the market, according to consulted experts.
Currently, the names of the 16 pharmaceutical companies investigated are kept confidential due to the deliberative nature of the process. However, official announcements are expected in the coming weeks, along with measures to strengthen oversight of the sector.
Are you interested in learning more about transparency in the health sector? Share this information on your social networks and follow our updates to stay up to date with the investigations. #HealthWithoutCorruption
Explore more related content:Keys to understanding the drug shortage in Mexico | How public tenders work in the health sector




